Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 2/20 | 0.41 |
| ▸ | TGM2 | P21980 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19371447 | 0.98 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3068902 | 0.89 | F2 (0.43) | MAPTALDH1A1CYP3A4CYP2C19F2 | |
| SCHEMBL13584249 | 0.87 | MEN1 (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL13584479 | 0.85 | MEN1 (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4100266 | 0.85 | MEN1 (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1676492 | 0.83 | GRIN2D (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2279831 | 0.83 | MEN1 (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28592175 | 0.82 | PEPD (0.52) | MEN1KMT2AMAOAMAOBMAPT | |
| Hydrochloric Acid SCHEMBL1115166 | 0.81 | GRIN2D (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5463340 | 0.81 | IDO1 (0.61) | IDO1MEN1KMT2AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112108187-B | Copper-supported catalyst of biguanide-based covalent organic framework material and preparation method and application thereof | 江南大学 | 2021-09-07 | — | — | CN | claimed |
| CN-112108188-B | Biguanide group covalent organic framework material supported palladium catalyst and application thereof | 江南大学 | 2021-08-10 | — | — | CN | claimed |
| CN-112108188-A | Biguanide group covalent organic framework material supported palladium catalyst and application thereof | 江南大学 | 2020-12-22 | — | — | CN | claimed |
| CN-112108187-A | Copper-supported catalyst of biguanide-based covalent organic framework material and preparation method and application thereof | 江南大学 | 2020-12-22 | — | — | CN | claimed |
| US-20200277255-A1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. | 2020-09-03 | — | — | US | claimed |
| US-10626085-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2020-04-21 | — | — | US | claimed |
| US-20180044283-A1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2018-02-15 | — | — | US | claimed |
| EP-3222614-A2 | BIGUANIDE COMPOUND AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-09-27 | — | — | EP | claimed |
| US-20170114008-A1 | NOVEL COMPOUND HAVING IMMUNE DISEASE TREATMENT EFFECT AND USE THEREOF | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-04-27 | — | — | US | claimed |
| CN-102725263-A | Biguanide derivative, method for preparing the same, and pharmaceutical composition comprising the biguanide derivative as an active ingredient | HANALL BIOPHARMA CO LTD | 2012-10-10 | — | — | CN | claimed |
| CN-1038248-C | Diguanide derivatives, process of preparation thereof and disinfetants containing them | OTSUKA CHEMCIAL CO LTD (JP) | 1998-05-06 | — | — | CN | claimed |
| CN-1065453-A | Biguanide derivative, its manufacture method and the Herb of Common violet that contains this derivative | OTSUKA CHEMICAL CO LTD (JP) | 1992-10-21 | — | — | CN | claimed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-11572341-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572341-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-114364780-A | Treatment liquid, kit, method for producing treatment liquid, method for cleaning substrate, and method for treating substrate | 富士胶片株式会社 | 2022-04-15 | — | — | CN | disclosed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| CN-1038248-C | Diguanide derivatives, process of preparation thereof and disinfetants containing them | OTSUKA CHEMCIAL CO LTD (JP) | 1998-05-06 | — | — | CN | disclosed |
| CN-1065453-A | Biguanide derivative, its manufacture method and the Herb of Common violet that contains this derivative | OTSUKA CHEMICAL CO LTD (JP) | 1992-10-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626085-B2 | Biguanide compound and use thereof | MKI67, GCG, GCKR | GRIN2D 1427/4885GRIN3B 497/4885GRIN1 770/4885 |
| US-20180044283-A1 | BIGUANIDE COMPOUND AND USE THEREOF | MKI67, GCG, GCKR | GRIN2D 1427/4885GRIN3B 497/4885GRIN1 770/4885 |
| US-11572341-B2 | Biguanide compound and use thereof | MKI67, GCG, GCKR | GRIN2D 1427/4885GRIN3B 497/4885GRIN1 770/4885 |
| US-20170114008-A1 | NOVEL COMPOUND HAVING IMMUNE DISEASE TREATMENT EFFECT AND USE THEREOF | NFATC1, CD14, CD209 | GRIN2D 3847/4885GRIN3B 2437/4885GRIN1 2762/4885 |
| US-11739072-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | GRIN2D 1756/4885GRIN3B 1408/4885GRIN1 1938/4885 |
| US-20200277255-A1 | BIGUANIDE COMPOUND AND USE THEREOF | MKI67, GCG, GCKR | GRIN2D 1427/4885GRIN3B 497/4885GRIN1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.